Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability under the Right to Health

Journal of Law, Medicine and Ethics 40 (2):234-250 (2012)

Abstract
Many medicines currently available on the market are simply too expensive for millions around the world to afford. Many medicines available in the developing world are only available to a small percentage of the population due to economic inequities. The profit-seeking behavior of pharmaceutical companies exacerbates this problem. In most cases, the price reductions required to make drugs affordable to a broader class of people in the developing world are not offset by the resultant increase in sales volume. Simply stated, in most of the developing world, it is more profitable to sell drugs to the very wealthy at high prices than it is to sell cheaper drugs to a greater number of people. As a result, medicines remain unaffordable for the vast majority of people in many parts of the world. While this might be an acceptable outcome for certain commodities, such as luxury goods, it is completely unacceptable for life-saving medicines. Therefore, in order to effectively address the global lack of access to medicines, the role pharmaceutical companies play in the international intellectual property regime must be critically examined
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1111/j.1748-720X.2012.00661.x
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

Our Archive


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 43,780
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

The Independence of Medical Ethics.Johan Brännmark - 2019 - Medicine, Health Care and Philosophy 22 (1):5-15.

Add more citations

Similar books and articles

Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (S1):3 - 23.
Priceless Goods: How Should Life-Saving Drugs Be Priced?Ian Maitland - 2002 - Business Ethics Quarterly 12 (4):451-480.
Priceless Goods: How Should Life-Saving Drugs Be Priced?Ian Maitland - 2002 - Business Ethics Quarterly 12 (4):451-480.

Analytics

Added to PP index
2012-07-13

Total views
24 ( #359,973 of 2,265,042 )

Recent downloads (6 months)
3 ( #449,910 of 2,265,042 )

How can I increase my downloads?

Downloads

My notes

Sign in to use this feature